Table 3.

Trial process chart

Visit	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7
Status	Screening	Baseline					Follow-up phase
Week	−4 ~ 0	0	1 (±3 day)	4 (±7 day)	8 (±7 day)	12 (±7 day)	16
Informed consent	●
Inclusion/exclusion criteria	●
Baseline characteristics	●
Risk factors	●
Medical history	●
Past medication history1	●
Family history	●
Randomization		●
Physical examination	●					●
Vital signs	●	●		●	●	●
Height/weight2	●	●		●	●	●
Blood analysis3	●					●
Pregnancy test4	●					●
ECG	●					●
Echocardiography	●					●
Exercise test	●					●
CMR5	●					●
CAG or CCTA	●
SF-36 questionnaire	●					●
BISF-W self-assessment questionnaire	●					●
Case drug distribution		●		●	●
Case drug collection				●	●	●
Trial evaluation
Adverse events	●	●	●	●	●	●	●
Patient’s compliance			●	●	●	●
Concomitant medications6		●	●	●	●	●

CMR; Cardiac magnetic resonance image, CAG; Coronary angiography, CCTA; Coronary CT angiography, ECG; Electrocardiogram.

¹The participant’s usual medication regimen continued unchanged throughout study duration.

²Check weight only after Visit 2.

³CBC: WBC, Hemoglobin, Hematocrit, Platelet; Chemistry: Total protein, Albumin, Globulin, Total bilirubin, AST; aspartate aminotransferase, ALT; alanine transaminase, ALP; alkaline phosphatase, BUN; blood urea nitrogen, Creatinine, Uric acid; Electrolyte: Na, K, Cl; NT-proBNP; N-terminal of the prohormone brain natriuretic peptide; hs-CRP; high-sensitivity c-reactive protein.

(NT-proBNP, hs-CRP: check visit 1 and visit 5).

⁴Women of child-bearing age.

⁵Stop all medications three days before CMR.

⁶Concomitant medications: beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin, and trimetazidine.